First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody as First-line Treatment for Patients with Non-Squamous Non-Small Cell Lung Cancer

Life Science

Tianjin Tasly Out-licenses US Rights to TCM Angina Drug in $50 Million Deal

Life Science

Aurora Cannabis’ $290-million deal to buy ICC Labs fuels surge in marijuana stocks

Cannabis, Life Science

2 Bay Area Biotechs Launch IPOs Worth a Combined $200 Million

Life Science

Innovent Approved for China Trial of CD47 I-O Drug

Life Science

Cadrock Raises $5 Million from China Investor for Antibiotic CAD Treatment

Life Science

Canadian cannabis ETF passes billion-dollar mark

Cannabis, Life Science

Canndescent Raises $13 Million to Broaden Portfolio & Expand into New States

Cannabis, Life Science

Mylan Strikes $463 Million Deal With Novartis for CF Product Line

Life Science

Driver, “A Cure for Cancer Treatment,” Launches in US and China

Life Science

Hansoh Pharma Plans Hong Kong IPO that Could Raise $1-$3 Billion

Life Science

Eccogene of Shanghai Completes $14.6 Million Funding Led by Sinopharm

Life Science

Zai Lab Raises $150 Million in US Secondary Offering

Life Science

BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo

Life Science

Life Science & Technology Weekly 159 – RootPath Receives $7 Million Seed Funding for Next-Gen Immuno-Oncology

Life Science, Technology